Predicting likelihood of response to combination therapy
View Patent ↗Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.
1. A method of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy, the method comprising:
(a) determining the expression level of the HoxB13 gene in a tissue or blood sample from the subject by preparing cDNA from HoxB13 mRNA extracted from the sample and quantifying the cDNA;
(b) comparing the expression level with reference expression levels of the HoxB13 gene in ER+ cells from reference breast cancer tumor cells that are (i) known to have high expression levels of the HoxB13 gene and/or (ii) known to have low expression levels of the HoxB13 gene;
(c) classifying the tumor cells from the subject as having high expression levels, or low expression levels, of HoxB13 based on the comparison in step (b);
(d) classifying the subject as likely to benefit from a combination endocrine therapy and mTOR inhibitor therapy if the subject has high HoxB13 and unlikely to benefit from the combination therapy if the subject has low HoxB13; and
(e) treating the subject with combination endocrine therapy and mTOR inhibitor therapy if the subject has high HoxB13 and not treating the subject with combination endocrine therapy and mTOR inhibitor therapy if the subject has low HoxB13.
2. A method of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy, the method comprising:
(a) determining the expression level of the HoxB13 gene in a tissue or blood sample from the subject by preparing cDNA from HoxB13 mRNA extracted from the sample and quantifying the cDNA;
(b) comparing the expression level with reference expression levels of the HoxB13 gene in ER+ cells from reference breast cancer tumor cells that are (i) known to have high expression levels of the HoxB13 gene and/or (ii) known to have low expression levels of the HoxB13 gene;
(c) classifying the tumor cells from the subject as having high expression levels, or low expression levels, of HoxB13 based on the comparison in step (b);
(d) classifying the subject as likely to benefit from a combination endocrine therapy and mTOR inhibitor therapy if the subject has high HoxB13 and unlikely to benefit from the combination therapy if the subject has low HoxB13; and
(e) recommending combination endocrine therapy and mTOR inhibitor therapy for the subject if the subject has high HoxB13 and not recommending combination endocrine therapy and mTOR inhibitor therapy for the subject if the subject has low HoxB13.
3. The method of claim 1 , wherein the preparing and quantifying of step (a) is by quantitative reverse transcription PCR.
4. The method of claim 1 , wherein the preparing and quantifying of step (a) comprises pre-amplification of the HoxB13 cDNA.
5. The method of claim 1 , wherein serum or plasma isolated from a blood sample from the subject is utilized in the determining step.
6. The method of claim 1 , wherein the expression level of the HoxB13 gene in circulating tumor cells or cell free mRNA is determined.
7. The method of claim 1 , wherein the sample comprises ER+ breast cancer tumor cells from the breast of the subject.
8. The method of claim 7 , wherein the sample tumor cells are from a ductal lavage or fine needle aspirate sample, and/or the sample tumor cells are microdissected to isolate one or more cells suspected of being breast cancer cells.
9. The method of claim 7 , wherein the sample tumor cells are from a formalin fixed paraffin embedded (FFPE) sample.
10. The method of claim 9 , wherein
the subject has undergone initial endocrine therapy for at least four years and the FFPE sample was taken before the initial endocrine therapy commenced; and
the subject is classified as likely to benefit from a combination extended endocrine therapy and mTOR inhibitor therapy if the subject has high HoxB13 and unlikely to benefit from the combination extended therapy if the subject has low HoxB13.
11. The method of claim 2 , wherein the sample is a formalin fixed paraffin embedded (FFPE) sample comprising ER+ breast cancer tumor cells from of the breast of the subject, and wherein
the subject has undergone initial endocrine therapy for at least four years and the FFPE sample was taken before the initial endocrine therapy commenced; and
the subject is classified as likely to benefit from a combination extended endocrine therapy and mTOR inhibitor therapy if the subject has high HoxB13 and unlikely to benefit from the combination extended therapy if the subject has low HoxB13.
12. The method of claim 1 , wherein the endocrine therapy comprises treatment with a selective estrogen receptor modulator (SERM), a selective estrogen receptor down-regulator (SERD), and/or an aromatase inhibitor (AI).
13. The method of claim 12 , wherein the endocrine therapy comprises treatment with tamoxifen, letrozole or anastrozole.
14. The method of claim 1 , wherein the mTOR inhibitor therapy comprises treatment with a rapamycin analog, a PI3K inhibitor or an Akt inhibitor.
15. The method of claim 14 , wherein the mTOR inhibitor therapy comprises treatment with temsirolimus, everolimus, or ridaforolimus wortmannin, demethoxyviridin, LY294002, perifosine, idelalisib, IC486068, IC87114, or perifosine.
16. The method of claim 1 , wherein the breast cancer tumor cells from the subject are from a primary tumor.
17. The method of claim 1 , wherein the breast cancer tumor cells from the subject are from a metastatic tumor.
18. The method of claim 1 , wherein the breast cancer tumor cells from the subject have a mutation that activates mTOR.